

MILBANK, TWEED, HADLEY & MCCLOY LLP

1 CHASE MANHATTAN PLAZA

NEW YORK, N.Y. 10005-1418

LOS ANGELES
213-892-4000
FAX: 213-828-5083

WASHINGTON, D.C.
202-835-7500
FAX: 202-835-7586

LONDON
020-7815-3000
FAX: 020-7815-3100

FRANKFURT
49-69-71914-3400
FAX: 49-69-71914-3500

MUNICH
49-89-25559-3000
FAX: 49-89-25559-3700

212-530-5000

FAX: 212-530-5219

JOHN M. GRIEM, JR.
PARTNER
DIRECT DIAL NUMBER
212-530-5429
FAX: 212-822-5429
E-MAIL: jgriem@milbank.com

BELING
8610-5123-5120
FAX: 8610-5123-5191

HONG KONG
852-2971-4888
FAX: 852-2840-0792

SINGAPORE
65-6428-2400
FAX: 65-6428-2500


TOKYO
813-3504-1050
FAX: 813-3595-2790

June 23, 2008

VIA FACSIMILE

Hon. Colleen McMahon
United States District Judge
Daniel Patrick Moynihan
United States Courthouse
500 Pearl Street, Room 640
New York, New York 10007

MEMO ENDORSED



Re: AstraZeneca AB, et al. v. Dr. Reddy's Laboratories, Ltd., et al.
07-civ-6790 (CM)(FM)

Dear Judge McMahon:

We write pursuant to the Court's May 5, 2008 Order "Rulings on Astra-Zeneca's Request for Infringement Discovery" ("the Order") and the Court's direction that AstraZeneca will have 30 days from the conclusion of the permitted discovery to decide whether to withdraw the instant action. The parties agree that today is the deadline for making that decision.

AstraZeneca has not been able to fully assess DRL's products or manufacturing processes to determine whether they improperly encroach on AstraZeneca's IP rights. Pursuant to the Order, AstraZeneca was permitted one deposition of DRL and limited document discovery of only portions of DRL's ANDA and DMF. Before that, AstraZeneca was permitted to ask 10 interrogatories and received samples selected by DRL. AstraZeneca took the deposition on May 23, and on June 16 wrote to DRL outlining the deficiencies in the witness's knowledge of DRL's manufacturing processes. AstraZeneca asked DRL to voluntarily produce certain additional documents and information discussed at the deposition that would aid AstraZeneca in determining whether DRL's ANDA Product would infringe AstraZeneca's patents. DRL has refused to provide this information.


MEMO
Endorsement

6/25/08
These we will proceed
to decide the
motion to dismiss
Colleen McMahon

Hon. Colleen McMahon
June 23, 2008
Page Two

Under the circumstances, because it has not been able to obtain the information necessary to fully analyze DRL's ANDA Product, AstraZeneca is not prepared to withdraw this action.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "John M. Grimm, Jr.", with a large, stylized flourish extending from the end of the signature.

John M. Grimm, Jr.

cc: Louis H. Weinstein, Esq.
Michael Imbacuan, Esq.
Counsel for Defendants Dr. Reddy's Laboratories, Ltd., et al. (via facsimile)